Determining the impacts of the immune system on cancer cells is important for the development of cancer treatments. Currently, there are two main strategies for eliciting antitumour effects via the immune system. First, immune system components, such as antibodies, natural killer (NK) cells or other immune cells, including T cells, which are born to effectively instruct passive immunity, can be exploited as 'killing' factors. After being activated by interleukin-2(IL-2), NK cells can hunt and kill tumour cells directly, without a requirement for prior sensitization for efficient tumour cell lysis. 3 In contrast, antibodies, from B cells or injections, bind to antigens or receptors on the surface of cancer cells, destroying protumour cytokines and automatically blocking the interaction between cancer cells and the microenvironment. 4 Second, to establish active immunity, antigen presenting cells (APCs), such as dendritic cells (DCs), function as pivotal regulators of immune outcome, such as tolerance or immune activation. 5 After loading with tumour-associated antigen and proper antigen processing, DCs produce pro-inflammatory cytokines, which activate tumour-specific cytotoxic T lymphocytes (CTLs)
to induce immune-mediated killing. 6 However, as the sentinel APCs of the immune system, the maturation status of DCs determines the efficiency and ultimate success of their interaction with cancer cells because fully mature DCs can provide all three conventional T cell stimulatory signals, enabling the elicitation of potent anticancer immunity; this kind of productive interface with dying cells is regarded as a necessary form of communication. 7 Although killing cancer cells is the most direct method of immune clearance, it has recently been found that prior to pathogen reproduction and transmission during an infection, the first batch of pathogen-infected cells actively commits suicide; then, the dead cell debris is quickly cleared by macrophages or neighbouring cells without affecting the normal functions of other cells. We have confirmed that this non-inflammatory cell death is programmed cell death (PCD).
PCD, or more specifically, apoptosis, is a unique strategy for protecting a host from every possible pathogen. 8 Through the activation of caspase-3, both the intrinsic and extrinsic pathways are activated and more than 500 cellular substrates are cleaved to execute the apoptosis program. The 'intrinsic' apoptotic pathway, is regulated by pro-apoptotic members of the BCL-2 family, which stimulates mitochondria to release molecules such as cytochrome c, 9 which
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• Immunogenic cell death (ICD) is defined by chronic exposure of damage-associated molecular patterns (DAMPs) in the tumour microenvironment (TME), which stimulates the dysfunctional antitumour immune system.
• The induction of ICD contributes to long-lasting protective antitumour immunity.
• ICD induction via physical therapy and combination therapy has emerged as novel cancer therapies.
F I G U R E 1 Schematic representation of the induction of immunogenic cell death (ICD).
After treatment with different ICD inducers, cancer cells are induced to undergo apoptosis, which leads to cell swelling and bursting. Subsequently, the dying cells express damageassociated molecular pattern (DAMPs) hallmarks, including the translocation of CRT from the endoplasmic reticulum to the cell surface, the release of high mobility group B1 from the nucleus, the extracellular secretion of adenosine triphosphate and the expression of HSPs on the cell surface together with pro-caspase-9 and apoptotic protease-activating factor 1 (APAF1), forms the apoptosome, a multiprotein complex induct PCD. 10, 11 In contrast, the 'death receptor' pathway, is carried out by the formation of a multiprotein complex containing FAS, adaptor protein FAS-associated death domain (FADD) 12 and pro-caspase-8, which is known as the death-inducing signalling complex (DISC).
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Normally, apoptotic cells are rapidly engulfed by macrophages, but unlike the swelling and rupturing that occur during the necrosis process, which are truly immunogenic, apoptotic cell death has long been hypothesized to be poorly immunogenic (or even tolerogenic).
14 However, some dying apoptotic cells release their cellular contents and these contents contain damage-associated molecular patterns (DAMPs), which act as danger signals to produce immunostimulatory effects, including the recruitment and activation of neutrophils, macrophages and other immune cells. 8 Moreover, the apoptotic nature of cell death is critical for determining immunogenicity. 15 Immunogenic cell death (ICD) is defined by the chronic exposure of DAMPs to the immune system, which may drive autoimmunity and promote immune-mediated elimination in the tumour microenvironment (TME) ( Figure 1 ). The above discussion indicates that it is essential to understand the emerging methods of ICD induction and apply them to clinical cancer treatments. 41 and shikonin (SK), 42 have been widely used in controlled studies as a criterion for the successful induction of ICD and the inhibition of tumour growth (Table 1) . Furthermore, (Table 2) .
| EMERG ING ME THODS OF ICD INDUC TION

| Nanotechnology serves to induce ICD
Nanotechnology is an excellent technology for application in cancer therapy. In recent years, nanoparticle encapsulation has been verified to improve the activity of chemotherapy drugs by controlling 64 the drug dosage precisely to decrease the toxicity of substances used in pharmacology and in a physical modality; nanopulse stim-
ulation (NPS) delivers ultrashort electrical pulses to tumour cells.
However, all of these cancer therapy effects have been found to be related to the induction of ICD.
| Nanosized drug carriers and nanopulse stimulation
To confirm the enhanced permeability and retention (EPR) effect of nanocarriers, 65, 66 Liu et al combined the traditional ICD chemical inducers mitoxantrone (MIT) and celastrol (CEL) at a ratio of 5:1
and then delivered this combination to a melanoma tumour site with a TME-responsive nanoparticle (NP). 67 After MIT and CEL were loaded on the TME-responsive NPs and injected into the tumour, 
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The proposed nanomedicine approach may be combined with ICD inducers to enhance antitumour effects and minimize the side effects of chemotherapeutic drugs.
| Nanopulse stimulation
Compared to drug-induced ICD, nanopulse stimulation (NPS), which uses ultrashort electrical pulses in the nanosecond range, seems to be safer and less invasive. Nanosecond pulses penetrate all cells and organelles in the tumour at high speed and large amplitude, 68 which allows internal calcium ions to rearrange. 69 The calcium ions 'escape' from the ER and trigger ER stress, prompting the release of more ROS. 70, 71 All these approaches are applied to cancer treatment. In several cancer cell lines, NPS first activates caspase 3/7 to induce cell apoptosis and ecto-CRT is then increasingly expressed on the cell surface. Surprisingly, the percentage of ecto-CRT-expressing cells is NPS energy-dependent and the ability of NPS to induce ecto-CRT expression is comparable to that of anthracycline treatment. Further, the secretion of HMGB1 and ATP is observed after NPS treatment. 
| Oncolytic virotherapy synergizes with the host immune system to induce ICD
In several clinical and preclinical studies, oncolytic virotherapy exerted the most effective antitumour results when potent viral oncolysis induced specific immune responses against tumour antigens.
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Nevertheless, the induction of ICD in the context of oncolytic virotherapy is an essential factor that contributes to both oncolytic effects and immune responses.
Oncolytic viruses (OVs) were first recognized for their unusual cancer-killing abilities; they directly kill cancerous tissues with almost no side effects, as they spare normal cells. 
| Advanced physical induction strategies for ICD
Chemical drug treatment has always been the main means of combating cancer development; however, the severe side effects of chemotherapy, such as pain and hair loss, have also added to patient suffering. In recent decades, many physical therapies, such as electrochemotherapy (ECT) in combination with inducible T cell costimulator (ICOS) activation, have been found to inhibit tumour growth, metastasis and angiogenesis. 59, 60 Moreover, studies have also demonstrated that the induction of ICD is responsible for the long-term antitumour response elicited by physiotherapy.
| Near-infrared photoimmunotherapy
Near-infrared photoimmunotherapy (NIR-PIT) is a combination therapy that includes near-infrared radiation and an antibody-photosensitizer conjugate 76 ; interestingly, the antibody acts as a 'guide' that directly locks onto cancer cells with overexpressed antigen on the plasma membrane, while the photoactivated silica-phthalocyanine photosensitizer IRDye700DX (IR700) is localized to the target cells and attracts the NIR light. Once target cancer cells are exposed to NIR light, a series of selective cytotoxic effects will be triggered and eventually results in cell death. 76,77 Nakajima et al elucidated the possible cytotoxic mechanism that induces the cell swelling and ICD induced by NIR-PIT. 45 After NIR light irradiation, minute plasma membrane damage causes ions and molecules of specific sizes to enter cells; similarly, Ogawa et al found that NIR-PIT-induced damage caused water to flow into cells, which led to obvious rapid swelling. 46 Thus, NIR-PIT-induced membrane damage is responsible for subsequent immunogenic signal exposure and release by dying cells.
NIR-PIT-treated tumour cells express increasing levels of calreticulin, HSP70 and HSP90 on the plasma membrane and rapid discharge of HMGB1 and ATP has also been detected. In addition, NIR-PIT-induced ICD can promote the maturation of immature DCs, which contribute to long-lasting antitumour immunity. Therefore, the results of the first NIR-PIT clinical trial are worth following.
| Oxygen-boosted photodynamic therapy (PDT) with C@HPOC
Photodynamic therapy (PDT) has been reported to have the ability to kill cancer cells through manipulating photosensitizers and oxygen to generate reactive ROS, which trigger phox-ER stress and induce antitumour immunity to eliminate residual or metastatic tumours effectively and selectively. 17, 33, 44 However, hypoxia in solid tumour environments is beneficial for promoting tumour metastasis, but the lack of oxygen is a severe factor that decreases the efficacy of PDT. 78, 79 To relieve the limiting effects of hypoxia on PDT, Chen 
| CONCLUSIONS AND FURTHER PERSPEC TIVES
Since 2005, when the definition of ICD was first proposed, 37 cancer treatment via host immunity has reached new heights. ICD makes dying cancer cells immunogenic and promotes DC maturation and IL-1β production; in addition to activating immune cells, ICD induces antigen presentation by APCs, resulting in a long-lasting antitumour response. 82 The mechanisms of ICD induction have been clearly classified into two modalities. 83 Type I ICD is induced through the collateral ER stress effect, indirectly inducing ICD-associated danger signalling without triggering ROS production and ER stress. In contrast, Type II ICD induction selectively targets the ER, inducing ER stress-dependent cell death, which is also immunogenic. 84 However, further research has shown that the exposure and release of DAMPs are not the only characteristics of ICD. MOMP stimulates the activity of NF-κB, which has recently been described as a vital immunogenic determinant of necroptotic cell death. 85 To confirm the role of immu- were increased in tumours responding to CICD, consistent with the activation of an antitumourigenic Th1 response. 19 All these data indicated that for antitumourigenic effects of CICD, both NF-κB activity and immunity are required and that CICD is an immunogenic form of cell death (Figure 3 ). Therefore, it is necessary to focus on ICD inducers or combination therapies that induce ICD.
In this review, we summarized the emerging methods of ICD induction, which are mostly combination therapies that use targeted drugs and medical technology to take advantage of the strengths of their components and compensate for the deficiencies of each component. These novel inducers elicit strong antitumour effects on cell lines and murine models via ICD induction; moreover, researchers have found that C@HPOC-mediated PDT and NPS can both trigger ICD signals in the TME, subsequently activating DC maturation and causing T lymphocyte-mediated antitumour immunity.
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Importantly, ICD not only inhibits primary tumours but also exerts abscopal effects and drastically suppresses distant or metastatic tumours. 
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